Literature DB >> 1335064

Effect of Hoe 140, a new B2 noncompetitive antagonist, on guinea pig tracheal bradykinin receptors.

A Trifilieff1, A Da Silva, Y Landry, J P Gies.   

Abstract

We investigated the effect of the new B2 antagonist D-Arg0[Hyp3,Thi5, D-Tic7, Oic8]bradykinin (BK) (Hoe 140) on the binding of [3H]BK to membranes from guinea pig trachea with respect to the presence of the epithelium. Scatchard analysis of equilibrium data with [3H]BK revealed a single class of binding sites in the epithelium denuded trachea membrane preparation (E-) with a dissociation constant (Kd) of 55 pM and a Bmax of 0.71 fmol.mg tissue-1. When intact trachea (E+) was used, two binding sites were detected: a saturable high-affinity one (Kd of 40 pM and Bmax of 0.69 fmol.mg tissue-1) and a low-affinity one, not really saturable, with a Kd over 180 nM and a Bmax over 18 fmol.mg tissue-1. In guinea pig ileum, a tissue thought to contain B2 receptors, one class of binding sites was detected with a Kd of 209.3 pM and a Bmax of 16.2 fmol.mg tissue-1. In competition experiments ([3H]BK from 0.3 to 0.5 nM), similar results were obtained in (E +/-) and in ileum membrane preparations. B1 ligands did not displace [3H]BK binding, demonstrating the lack of B1 receptors. BK and B2 antagonist, except Hoe 140, fully displaced [3H]BK with Hill coefficients close to the unity. In competition studies only the high-affinity site was labeled by [3H]BK, in the (E+) preparation, as suggested by the inhibition constant value of unlabeled BK. Hoe 140 fully displaced [3H]BK in competition experiments, but with a Hill coefficient significantly less than unity, suggesting the presence of two binding sites for this compound in the three preparations used.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335064

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Pharmacological and functional characterization of the guinea-pig B2 bradykinin receptor stably expressed in CHO-K1 cell line.

Authors:  C Robert; D Pruneau; J-L Paquet
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Effects of WIN 64338, a nonpeptide bradykinin B2 receptor antagonist, on guinea-pig trachea.

Authors:  D Scherrer; L Daeffler; A Trifilieff; J P Gies
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

3.  Bradykinin increases Na(+)-K(+) pump activity in cultured guinea-pig tracheal smooth muscle cells.

Authors:  A M Dodson; K J Rhoden
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Bradykinin binding sites in healthy and carcinomatous human lung.

Authors:  A Trifilieff; E Lach; P Dumont; J P Gies
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  Biphasic increase in cytosolic free calcium induced by bradykinin and histamine in cultured tracheal smooth muscle cells: is the sustained phase artifactual?

Authors:  Y Amrani; A Da Silva; O Kassel; C Bronner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

6.  Bradykinin-induced contraction of guinea pig lung in vitro.

Authors:  E Lach; A Trifilieff; M Mousli; Y Landry; J P Gies
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

7.  Involvement of B2 receptors in the bradykinin-induced relaxation of guinea-pig isolated trachea.

Authors:  A Da Silva; Y Amrani; A Trifilieff; Y Landry
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

8.  Effects of a novel nonpeptide bradykinin B2 receptor antagonist on intestinal and airway smooth muscle: further evidence for the tracheal B3 receptor.

Authors:  S G Farmer; M A DeSiato
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

9.  Activity of Bradykinin B2 Receptor Is Regulated by Long-Chain Polyunsaturated Fatty Acids.

Authors:  Jose Candelario; Mirianas Chachisvilis
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.